Sort
50,496 grants matching “lung cancer”
Immunobiology of Lung Injury and Fibrosis
$847,613Bethany B. Moore · University Of Michigan At Ann Arbor · R35 · FY2019 · HL
CLUE STUDIES--EVALUATING BIOMARKERS OF CARCINOGENESIS
$847,363Johns Hopkins University · U01 · FY2002 · CA
Molecular Biology of the Metastatic Phenotype
$847,050Patricia Schriver Steeg · Division Of Clinical Sciences - Nci · ZIA · FY2012 · CA
Vaccine and Drug Combination Therapy for Human Cancers
$847,016James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Vaccine and radiation for the therapy of human cancers
$847,016James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Cytokine Regulation of Normal and Neoplastic Hematopoietic Cell Growth
$846,976Francis W. Ruscetti · Basic Sciences · Z01 · FY2007 · CA
Core G: Clinical Cohort and Comorbidity Research
$846,888Mari M Kitahata · University Of Washington · P30 · FY2022 · AI
Optimizing Ultrasensitive DNA methylation detection for lung cancer and other malignancies
$846,821James G. Herman · University Of Pittsburgh At Pittsburgh · U2C · FY2024 · CA
Determining the Fate of Transmembrane Proteins
$846,720Allan M Weissman · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines
$846,484James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Clinical trials employing cancer vaccine combination therapies
$846,484James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Ultrafine Particulate Monitor for Personal Exposure Assessment
$845,918David Michael Woolsey · Aerodyne Microsystems, Inc. · R44 · FY2022 · ES
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
$845,852Joseph Patti · Agilvax, Inc. · R44 · FY2019 · CA
Genomic predictors of smoking and lung cancer risk
$845,698Christopher I. Amos · Baylor College Of Medicine · U19 · FY2022 · CA
Imaging of Hematologic and Oncologic Disorders
$845,646Brian D. Ross · University Of Michigan At Ann Arbor · R35 · FY2019 · CA
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
$845,601Jane Hoyt Buckner · Benaroya Research Inst At Virginia Mason · R01 · FY2023 · CA
A Phase II Trial of ACAPHA in Former Smokers with IEN.
$845,564British Columbia Cancer Agency · U01 · FY2005 · CA
National Lung Screening Trial (NLST)
$845,536University Of Colorado Denver · N01 · FY2009 · CA
Intercepting progression from pre-invasive to invasive lung adenocarcinoma
$845,268Nasser Khaled Altorki · Weill Medical Coll Of Cornell Univ · UH3 · FY2021 · CA
ENGINEERING TCR-T CELLS TO TARGET HUMAN ENDOGENOUS RETROVIRUSES FOR NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY
$845,250Duke University · · FY2025 · Defense Health Agency
Investigating the Roles of Patient Beliefs, and Physician Communication on Disparities in Lung Cancer Screening
$844,984Minal S Kale · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · MD
DUAL UP- AND DOWNSTREAM TARGETING OF POU2F3 IN SMALL CELL LUNG CANCER
$844,231H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. · · FY2025 · Defense Health Agency
Cancer Gene Discovery to Identify Targetable Targets
$843,904Carlo M Croce · Ohio State University · R35 · FY2021 · CA
DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs
$843,796Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Nox family NADPH oxidases: roles in innate immunity and inflammatory disease
$843,127Thomas Leto · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI